Journal
CLINICAL LUNG CANCER
Volume 23, Issue 5, Pages E325-E329Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2022.04.005
Keywords
Limited-stage SCLC; Pembrolizumab; Olaparib; Concurrent chemoradiotherapy
Categories
Funding
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA
- NIH/NCI Cancer Center Support Grant [P30 CA008748]
Ask authors/readers for more resources
The KEYLYNK-013 study evaluates the efficacy and safety of adding pembrolizumab to concurrent chemoradiotherapy (CCRT) in limited-stage SCLC patients, as well as the efficacy and safety of pembrolizumab with or without olaparib post CCRT. Enrollment for the study is currently ongoing.
Background: The current standard of care for patients with newly diagnosed limited-stage small-cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT). The prognosis remains poor due to the aggressiveness and high risk of progression or relapse of SCLC even if an initial response is achieved. Therefore, there is an urgent unmet clinical need in this population. The multicenter, phase 3, randomized, placebo-controlled, double-blind KEYLYNK-013 study evaluates the addition of pembrolizumab to CCRT followed by pembrolizumab with or without olaparib in participants with previously untreated limited-stage SCLC. (ClinicalTrials.gov: NCT04624204). Methods: Eligible participants aged ???18 years with newly diagnosed, pathologically confirmed, limited-stage (ie, stage I-III) SCLC will be randomized 1:1:1 to CCRT (ie, etoposide plus carboplatin or cisplatin for 4 cycles and standard thoracic radiotherapy) plus pembrolizumab (Groups A and B) or CCRT plus placebo (Group C). In the absence of disease progression, participants will receive pembrolizumab plus placebo (Group A), pembrolizumab plus olaparib (Group B), or placebo (Group C). Dual primary endpoints are progression-free survival per RECIST version 1.1 by blinded independent central review and overall survival. Results: Enrollment began in December 2020 and is ongoing at approximately 150 sites. Conclusions: KEYLYNK-013 will provide valuable information on the efficacy and safety of pembrolizumab plus CCRT and pembrolizumab with or without olaparib post CCRT in participants with limited-stage SCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available